No Data
Solid Biosciences Stock Jumps 11% Post-market on FDA Update
RBC Capital Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Cuts Target Price to $58
PTC Therapeutics Price Target Lowered to $58 From $63 at RBC Capital
RBC Cuts Price Target on PTC Therapeutics to $58 From $63, Keeps Outperform Rating
Insider Sale: CHIEF EXECUTIVE OFFICER of $PTCT (PTCT) Sells 8,279 Shares
Insiders At PTC Therapeutics Sold US$1.2m In Stock, Alluding To Potential Weakness